ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CEL Celadon Pharmaceuticals Plc

61.00
1.50 (2.52%)
22 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Celadon Pharmaceuticals Plc LSE:CEL London Ordinary Share GB00BDQYGP38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 2.52% 61.00 57.00 65.00 61.00 59.50 59.50 12,246 14:00:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Investment Advice 149k -7.14M -0.1082 -5.64 39.26M

Re Directorate

15/11/2000 7:01am

UK Regulatory


RNS Number:1287U
Celsis International PLC
15 November 2000



CELSIS INTERNATIONAL PLC
Appoints New Chief Executive

Celsis International plc is today pleased to announce the appointment of Jay
LeCoque as full-time Chief Executive Officer.

Mr. LeCoque joins Celsis from OurHouse.com, the top rated internet site
focused on the "home", consistently featured as one of the world's top 20
most visited internet shopping sites by MediaMetrix. Mr. LeCoque originally
joined Celsis in April 1995 as Director of Global Business Development for
the personal care industries.  He was then appointed head of Sales and
Marketing in the Americas, before taking on the role of General Manager of
the Americas and helping Celsis to secure its first year of profitability.
Previously Mr. LeCoque worked for Valois, a global supplier to the
pharmaceutical and personal care industries, and Baxter International Inc. in
a variety of sales and marketing roles. Mr. LeCoque holds a MBA from
Northwestern University.

Jack Rowell, the acting CEO for the last two years, will resume his role as
Non-Executive Chairman of the Board. Mr. LeCoque was appointed to the Board
on the 15th November 2000, and will now take the lead of the recently
strengthened executive team, consisting of Christian Madrolle (Group Finance
Director) and Peter Grant (Director of Technology and Business Development).
Dr. Chris Evans resumes his original role as a Non-Executive Director.

Jack Rowell, Non-Executive Chairman of Celsis International plc, commented:
"I am pleased to announce the appointment of Jay LeCoque, and to welcome him
back to Celsis as Chief Executive Officer.  Jay joins us at an exciting
period in the development of the Company. The management team have worked
hard to establish Celsis as an innovative and profitable company producing
sustainable revenue growth, having turned a loss of #4.1m into a profit of
#3.0m within three years.  The Board has immense confidence in Jay's
experience, and his ability to continue the profitable growth of Celsis -
leading the management team into new markets whilst driving development and
innovation."

Dr. Chris Evans, Non-Executive Director of Celsis International plc,
commented:

"With an excellent management team now in place, I feel that Celsis is
ideally positioned for growth.  Jay LeCoque is exactly the sort of person
needed to drive the development of business, and with the experienced
guidance of Jack Rowell, I believe that investors can be confident in the
team's ability to create shareholder value.  I would also like to take this
opportunity to thank Jack for working beyond the call of duty in fulfilling
his role as acting CEO for the last two years."

Enquiries

Celsis International plc
Dr Peter Grant,
Technology and Business Development Director     +44 (0) 1223 426 008
Jenny Parsons, Corporate Communications          +44 (0) 1223 426 008

Brunswick Group
Melissa Miller/Juliet Marshall                   +44 (0) 20 7404 5959

Notes to Editors

Celsis International plc

Celsis International plc specialises in the development and supply of rapid
diagnostic and monitoring systems to detect and measure microbial
contamination.  It has successfully developed tests for use in the food,
beverage, pharmaceutical, cosmetic and toiletries industries.  These tests
are based upon the technology of ATP Bioluminescence; such tests detect the
presence of microbial contamination by monitoring light emitted when
adenosine triphosphate ("ATP"), a naturally occurring substance present in
all living organisms, is brought into contact with luciferase, an enzyme
produced by fireflies.



1 Year Celadon Pharmaceuticals Chart

1 Year Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock